Trial
NCT03263091
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Kyntra Bio
Collaborators
AstraZeneca; Astellas Pharma Inc
Condition
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
Intervention
Roxadustat
Why stopped
Study did not meet its primary efficacy endpoint.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-01